NBIX

Neurocrine Biosciences Inc
Data: 2026-03-27
$128.32
Price
-3.10%
Change
$160.18
52W High
$84.23
52W Low

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Quick Stats
Mar 27, 2026

61.6

AI Score

BUY

0.65

Volume Ratio

May 04, 2026

Next Earnings

16

+ve Days (30d)

13

-ve Days (30d)

NBIX Stock Summary

Last updated Mar 27, 2026

NBIX is currently trading at $128.32, positioned below its 200-day moving average of $137.05, suggesting bearish momentum. The stock has a 52-week range of $84.23 to $160.18.

Technical Analysis: The 50-day moving average stands at $132.14, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 45.043, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.04, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates NBIX at 61.6/100 with a BUY recommendation.

NBIX (Neurocrine Biosciences Inc) Indicators

Last updated Mar 27, 2026

Indicator Value
RSI(14) 45.043
CMF (20) -0.04
ROC (10) -1.125
ADX (14) 10.876
Indicator Value
MACD (12,26,9) -0.779
AROONOSC (14) 7.143
WILLAMS %R (14) -59.546
MFI (14) 43.546
NBIX Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

NBIX Price vs Max Options Open Interest
NBIX Max Change In Options Open Interest

NBIX Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

NBIX Daily Out of Money Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

NBIX Daily In the Money Options - Sort by Max open Interest (near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

NBIX Most Active Options by Volume(near term)

30th March 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Neurocrine Biosciences Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

NBIX Moving Averages Analysis

NBIX (Neurocrine Biosciences Inc) Simple Moving Averages

Moving Averages are last updated Mar 27, 2026

Days MA
10 129.54
20 129.85
30 129.65
50 132.14
100 138.81
200 137.05

NBIX Fundamental Analysis

P/E (Forward) 22.4719
P/E (Trailing) 28.2949
Market Cap ($) 13.3 billion
Earnings/Share ($) 4.68
Net Proft Margin (%) 0.1673
Dividend/Share ($) --
EPS Estimate Current Year ($) 7.9582
EPS Estimate Next Year ($) 9.7204
WallStreet Target Price ($) 178.0411
Most Recent Quarter